Press Releases - Bristol Myers Squibb
Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio. March 15, 2024. FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy. March 14, 2024.
Bristol Myers Squibb Strengthens Neuroscience Portfolio with ...
Dec 22, 2023 · Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics. Transaction Delivers KarXT, a First-in-Class M1 / M4 Muscarinic Receptor Agonist, with Differentiated Efficacy and Safety. KarXT Is a Potential First-in-Class Treatment for Schizophrenia and as an Adjunctive Therapy, and First-in-Disease Treatment ...
Bristol Myers Squibb - Bristol Myers Squibb to Acquire Turning …
Jun 3, 2022 · Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company. Acquisition Brings Repotrectinib, a Potential Best-in-Class, Next-Generation ROS1/NTRK Inhibitor with Differentiated Duration of Response for Patients with ROS1-positive First-Line Non-Small Cell Lung Cancer; Expected to Launch in 2023.
Bristol Myers Squibb - Bristol Myers Squibb Completes Acquisition …
Mar 18, 2024 · Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio. KarXT, Karuna’s Lead Asset, Is a Potential First-in-Class Treatment for Schizophrenia with Multi-Billion Dollar Sales Potential Across Multiple Indications. PRINCETON, N.J.-- (BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today ...
Bristol Myers Squibb - U.S. FDA Approves Bristol Myers Squibb’s …
Jun 24, 2022 · Bristol Myers Squibb is inspired by a single vision—transforming patients’ lives through science. The goal of the company’s cancer research is to deliver medicines that offer each patient a better, healthier life and to make cure a possibility.
Corporate news details - Bristol Myers Squibb
Oct 8, 2023 · Through this acquisition, Bristol Myers Squibb will add KRAZATI, an important lung cancer medicine, to its commercial portfolio. The company gains access to several promising clinical assets that complement its oncology pipeline and are strong candidates for single agent development and combination strategies.
Bristol Myers Squibb - Bristol Myers Squibb Announces First …
Dec 12, 2022 · PRINCETON, N.J.-- (BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced the first disclosure of results and presentation of new research from its multiple myeloma portfolio across targets and molecular approaches at the 64 th American Society of Hematology (ASH) Annual Meeting and Exposition, underscoring the company’s commitment ...
Bristol Myers Squibb - Bristol Myers Squibb Adds Premier ...
Dec 26, 2023 · Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio. Transaction Brings RayzeBio’s Differentiated Actinium-Based Radiopharmaceutical Platform, Including Rich Pipeline of Multiple Drug Development Programs, to Bristol Myers Squibb’s Leading Oncology Franchise. Lead Program, RYZ101, in Phase 3 ...
Bristol Myers Squibb - Bristol Myers Squibb Reports Fourth …
Feb 2, 2023 · Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022. Reports Fourth Quarter Revenues of $11.4 Billion; Full-Year Revenues of $46.2 Billion. Fourth Quarter Revenues from In-Line Products and New Product Portfolio were $9.0 Billion, an Increase of 7%, or 12% When Adjusted for Foreign Exchange.
Bristol Myers Squibb - Bristol Myers Squibb Reports First Quarter ...
Apr 25, 2024 · Bristol Myers Squibb is executing a strategic productivity initiative that will drive approximately $1.5 billion in cost savings by the end of 2025, the majority of which will be reinvested to fund innovation and drive growth.